SCHEMBL23847019

SCHEMBL23847019

COc1ccc(N)cc1S(=O)(=O)Nc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
LMNA P02545 2/20 0.61
ALOX12 P18054 1/20 0.61
CA12 O43570 1/20 0.58
CA9 Q16790 1/20 0.58
ALPL P05186 1/20 0.55
MAPT P10636 2/20 0.55
ALDH1A1 P00352 2/20 0.55
GLA P06280 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
TSHR P16473 1/20 0.55
BRD4 O60885 1/20 0.55
BRD2 P25440 1/20 0.55
BRD3 Q15059 1/20 0.55
SMN1; SMN2 Q16637 5/20 0.54
HTT P42858 1/20 0.53
RECQL P46063 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23846529 0.92 ALPL (0.60) MEN1KMT2ALMNAALOX12ALPL
SCHEMBL23846503 0.87 SMN1; SMN2 (0.71) MEN1KMT2ALMNAALPLALDH1A1
SCHEMBL25754779 0.86 MEN1 (0.80) MEN1KMT2ALMNAALPLALDH1A1
SCHEMBL25754817 0.86 NPSR1 (0.62) MEN1KMT2ALMNAALPLMAPT
SCHEMBL17980891 0.86 MAPT (0.60) MEN1KMT2ALMNAALOX12ALPL
SCHEMBL23833758 0.86 RECQL (0.73) LMNAALPLALDH1A1SMN1; SMN2RECQL
SCHEMBL23846500 0.86 LMNA (0.73) MEN1KMT2ALMNAALPLMAPT
SCHEMBL23847027 0.85 MEN1 (0.59) MEN1KMT2ALMNAALOX12ALPL
SCHEMBL23846535 0.84 ALPL (0.59) MEN1KMT2ALMNAALOX12ALPL
SCHEMBL23833737 0.82 MEN1 (0.63) MEN1KMT2ALMNAALOX12ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
WO-2021188880-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 MEN1 3902/4885KMT2A 4864/4885LMNA 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.